Company profile

AnaptysBio, Inc.

Pipeline2 assets

dostarlimabJemperli / PD-1 / antibody / Oncology
Endometrial cancerApprovedapproveddMMR pan tumorsApprovedapprovedRectal cancerbeing studied
imsidolimabIL-36R / antibody / Dermatology/Inflammation
Generalized pustular psoriasisBLA submitted/acceptedFDA target action date December 12, 2026US

Latest news7 items

Sep 21, 2026

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA

Presentation / Abstract • Phase 2ESMO late-breaking abstract presentation Sun, Oct 25, 2026

Sep 1, 2026

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C.

May 12, 2026

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced appointment of Chris Murphy as CFO Announced appointments of Susannah Gray, former CFO

May 11, 2026

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with

May 4, 2026

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate

Apr 24, 2026

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro /GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) --

Apr 20, 2026

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.